| 摘要 |
The present invention relates to ligands of the CD47, to agents binding these ligands and their uses. More particularly, the present invention relates to the uses of monoclonal antibodies specific to the CD47, thrombospondin, Tp47, SIRP alpha , and fragments thereof, and to the use of soluble CD47-Fc, in pharmaceutical compositions for the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases as well as in the treatment of graft rejection and/or chronic lymphocytic leukemia. |
